

BAL PHARMA LIMITED
Regd Office : # 21&22, Bommasandra Industrial Area, Bangalore
CIN : L85110KA1987PLC008368

Disclosure as per Regulation 46 and 62 of SEBI (LODR) Regulations.

Sl. No.	Particulars as per LODR	Y/N/NA	URL	Remarks
1	(a) Details of business	Y	https://www.balpharma.com/investors	
2	(b) Terms and conditions of appointment of independent directors	Y	https://www.balpharma.com/investors/id	
3	(c) Composition of various committees of board of directors	Y	https://www.balpharma.com/investors/bd	
4	(d) Code of conduct of board of directors and senior management personnel	Y	https://www.balpharma.com/investors/cc	
5	(e) Details of establishment of vigil mechanism/ Whistle Blower policy	Y	https://www.balpharma.com/investors/wbp	
6	(f) Criteria of making payments to non-executive directors, if the same has not been disclosed in annual report	Y	https://www.balpharma.com/investors/ned	
7	(g) Policy on dealing with related party transactions	Y	https://www.balpharma.com/investors/rpt	
8	(h) Policy for determining 'material' subsidiaries	Y	https://www.balpharma.com/investors/sub	

9	<p>(i) Details of familiarization programmes imparted to independent directors including the following details:- (i) Number of programmes attended by independent directors (during the year and on a cumulative basis till date) (ii) Number of hours spent by independent directors in such programmes (during the year and on cumulative basis till date), and (iii) Other relevant details</p>	Y	https://www.balpharma.com/investors/ind	
10	<p>(j) The email address for grievance redressal and other relevant details</p>	Y	https://www.balpharma.com/investors/gr	
11	<p>(k) Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances</p>	Y	https://www.balpharma.com/investors/ig	
12	<p>(l) Financial information including: (i) Notice of meeting of the board of directors where financial results shall be discussed (ii) Financial results,</p>	Y	https://www.balpharma.com/investors/fin	

	on conclusion of the meeting of the board of directors where the financial results were approved (iii) Complete copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report etc.			
13	(m) Shareholding pattern	Y	https://www.balpharma.com/investors/shp	
14	(q) Items published in the newspaper: (a) financial results, as specified in regulation 33, along-with the modified opinion(s) or reservation(s), if any, expressed by the auditor: (b) notices given to shareholders by advertisement.	Y	https://www.balpharma.com/investors/pr	
15	(r) All credit ratings obtained by the entity for all its outstanding instruments, updated immediately as and when there is any revision in any of the ratings	Y	https://www.balpharma.com/investors/cr	
16	(s) Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year, uploaded at least 21 days prior to the date of the annual general meeting which has been called to inter alia	Y	https://www.balpharma.com/investors/sa	

	consider accounts of that financial year			
17	(t) Secretarial compliance report	Y	https://www.balpharma.com/investors/sec	
18	(u) Disclosure of the policy for determination of materiality of events or information	Y	https://www.balpharma.com/investors/ms	
19	(v) Disclosure of contact details of key managerial personnel who are authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s)	Y	https://www.balpharma.com/investors/kmp	
20	(w) All such events or information which has been disclosed to stock exchange(s) under regulation 30 of LODR	Y	https://www.balpharma.com/investors/lodr	
21	(z) Annual return as provided under section 92 of the Companies Act, 2013 and the rules made thereunder.	Y	https://www.balpharma.com/investors/ar	
22	(n) Details of agreements entered into with the media companies and/or their associates, etc.	NA		The Company has not entered into any agreement with media companies

23	<p>(o) Schedule of analysts or institutional investors meet and presentations made by the listed entity to analysts or institutional investors. Explanation: For the purpose of this clause 'meet' shall mean group meetings or group conference calls conducted physically or through digital means</p> <p>(oa) Audio or video recordings and transcripts of post earnings/quarterly calls, by whatever name called, conducted physically or through digital means, simultaneously with submission to the recognized stock exchange(s), in the following manner:</p> <p>(i) The presentation and the audio/video recordings shall be promptly made available on the website and in any case, before the next trading day or within twenty-four hours from the conclusion of such calls, whichever is earlier</p> <p>(ii) The transcripts of such calls shall be made available on</p>	NA		We have not made any presentations to the analysts or institutional investors
----	---	----	--	---

	the website within five working days of the conclusion of such calls			
24	(p) New name and the old name of the listed entity for a continuous period of one year, from the date of the last name change	NA		The name of the Company has not changed in recent past.
25	(x) Statements of deviation(s) or variation(s)	NA		Auditors has issued unqualified reports .
26	(y) Dividend distribution policy by listed entities based on market capitalization	NA		Not applicable for our Company.

For Bal Pharma Ltd

SHAILES
H SIROYA

Digitally signed by SHAILES SIROYA
DN: cn=shailes, o=BAL PHARMA LTD, email=shailes@balpharma.com, c=IN
SHAILES SIROYA, o=BAL PHARMA LTD, email=shailes@balpharma.com, c=IN
SHAILES SIROYA, o=BAL PHARMA LTD, email=shailes@balpharma.com, c=IN
SHAILES SIROYA, o=BAL PHARMA LTD, email=shailes@balpharma.com, c=IN
SHAILES SIROYA, o=BAL PHARMA LTD, email=shailes@balpharma.com, c=IN
SHAILES SIROYA, o=BAL PHARMA LTD, email=shailes@balpharma.com, c=IN
SHAILES SIROYA, o=BAL PHARMA LTD, email=shailes@balpharma.com, c=IN
SHAILES SIROYA, o=BAL PHARMA LTD, email=shailes@balpharma.com, c=IN
SHAILES SIROYA, o=BAL PHARMA LTD, email=shailes@balpharma.com, c=IN

Authorised Signatory